Midsona (OM:MSON B) Stock Looks Cheap Despite Mixed Q3 Results

Midsona walked into today with a bruised chart and a bargain label. The share price closed at SEK9.74 on 22 October, leaving the stock well below many analysts’ cash flow estimates and trading on a single digit P/E compared with richer European food peers.

Then Q3 2026 landed. Revenue came in at SEK910 million with net income of SEK39 million, and the real story sat on the balance sheet. Cash and leverage moved in the right direction, which matters far more for long term holders than one quarter’s modest top line and earnings print.

Like the Midsona story but want more balance sheet resilience with clearer earnings momentum? Check out our screener of list of solid balance sheet and fundamentals stocks (204 results) as a benchmark set of ideas.

Q3 2026 Earnings Summary

• Revenue (Q3 2026 vs. Q3 2025): SEK910 million vs. SEK895 million (up 1.7%)
• Net Income (Q3 2026 vs. Q3 2025): SEK39 million vs. a loss of SEK15 million (returned to profit)
• Basic EPS (Q3 2026 vs. Q3 2025): SEK0.27 vs. a loss of SEK0.10 per share (moved back into positive territory)
• EBIT Margin (Q3 2026 vs. Q3 2025): 5.0% vs. 5.0% (stable year on year)

Ask Charlie what Midsona’s shift from contract work means for growth.

Midsona earnings, profits and balance sheet support cautious optimism

For a cautiously bullish view on Midsona, the numbers give some backing. EBIT of SEK46m held margin at 5.0% while reported sales edged higher, which shows the mix shift toward higher quality volumes is not eroding profitability. Cash flow of SEK57m and leverage around 1.0x point to a sturdier balance sheet as low margin contracts are trimmed. The shift toward own consumer brands, with Division South growing organically and Nordics brands still inching ahead, fits the idea of a staple health and organic player tightening its focus.

Organic decline and weak regions keep the Midsona bear case alive

The more cautious narrative around Midsona also finds support. Organic sales fell 3.7%, with Division North dropping 10.3% and Health Foods and Consumer Health both moving backwards. That is a reminder that category relevance does not automatically translate into volume momentum. Most of the organic drop came from contract manufacturing reductions, which protects margins but still leaves reported demand soft. Recent share price performance, down 6% over one month and 16% over three months, suggests investors continue to treat this as a gradual turnaround rather than a clean recovery.

Scan whether Midsona’s shrinking organic volumes and unstable dividend track record signal deeper structural issues by reviewing our risk analysis for Midsona which shows 1 important warning sign

Hunt For Mispriced Earnings Power

Midsona now has a cleaner balance sheet story, but the share price still lags sentiment. The real opportunity is spotting companies that could be undervalued before that gap closes.

• Company 1 - 33% below our estimate - manages real asset funds that capture fee income as renewable projects and tax-efficient retail products secure fresh capital commitments.
• Company 2 - 44% below our estimate - converts a record order book in port automation and material handling into long delivery programs as customers upgrade equipment and maintenance services.
• Company 3 - 43% below our estimate - benefits as tolling fleets replace legacy units, marine clients adopt high end sonar, and defense buyers seek locally produced electronics.

Three companies from the same screener. Open all 191 potentially undervalued companies →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com